Business Context and Reporting Period
Zura Bio Ltd (ZURA), an emerging growth company incorporated in the Cayman Islands, filed this Form 8-K on May 21, 2025, to report the results of its Annual General Meeting of Shareholders held on the same date. The company is headquartered in Henderson, Nevada, and its Class A Ordinary Shares trade on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
The primary material event reported is the successful approval of shareholder proposals at the Annual Meeting. A quorum was present, and the following outcomes were recorded:
- Proposal 1 (Election of Directors): All nine (9) director nominees were elected. While most nominees received overwhelming support, two nominees faced significant dissent:
- Neil Graham received 31,627,753 votes "For" but 1,137,017 votes "Against".
- Jennifer Jarrett received 31,553,052 votes "For" but 1,207,643 votes "Against".
- Other nominees received between 54,181 and 288,250 votes "Against".
- Proposal 2 (Ratification of Auditors): Shareholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 44,576,844 "For", 36,032 "Against", and 30,145 "Abstain".
- Proposal 3 (Adjournment): This proposal was not put to a vote because Proposals 1 and 2 were approved by the requisite number of votes.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, financial guidance, or specific risk factors. It references a Definitive Proxy Statement on Schedule 14A filed on April 23, 2025, for further details on the proposals. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the specific reasons for the elevated "Against" votes for directors Neil Graham and Jennifer Jarrett by reviewing the April 23, 2025, Schedule 14A Proxy Statement.
- Confirm the total number of shares outstanding and the percentage of shares represented by the "Broker Non-Votes" (11,838,916) to assess the impact on voting power.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains no financial metrics.
- Monitor future filings for any changes in board composition or auditor engagement terms following the ratification.